Advanced Filters
noise

Semaglutide Clinical Trials

A listing of Semaglutide medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 67 clinical trials
M Mehdi Farokhnia, M.D., M.P.H.

Semaglutide Therapy for Alcohol Reduction (STAR)

Background Alcohol use disorder (AUD) is a problematic pattern of alcohol use accompanied by clinically significant medical consequences. Medications can help most people reduce their drinking, but the number is limited, and additional treatment options are needed. Objective To test if a medication named Semaglutide is safe and may reduce …

18 - 110 years of age All Phase 2
t tamer abdelaziz

Effect of Itopride on Semaglutide Gastroparesis

Semaglutide delays gastric emptying and increases the risk of aspiration with anesthesia; So, the addition of prokinetics as Itopride, could enhance gastric emptying and hasten surgery. The investigator will evaluate the effect of Itopride on Semaglutide-induced gastroparesis and residual gastric contents after 8 hours of fasting by gastric ultrasound before …

40 - 60 years of age Female Phase 4
R Roham Foroumadi, M.D.

Bariatric Surgery vs. Semaglutide vs. Tirzepatide

The recent introduction of the new generation of anti-obesity medications (AOMs) will change the future of obesity treatment. These highly effective medications, such as high-dose semaglutide and tirzepatide, are hormone analogues that augment the incretin function and exert multiple physiological effects by activating glucagon-like peptide-1 (GLP-1) and/or glucose-dependent insulinotropic polypeptide …

18 - 70 years of age All Phase 4
C Caroline K Kramer, MD PhD

Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination

Semaglutide is a medication from the class of drugs called glucagon-like peptide-1 agonists that promote weight loss. There is little clinical data on the best strategy to achieve weight maintenance following weight reduction induced by semaglutide. For people who need to discontinue treatment, it is unknown whether the weight regain, …

18 - 75 years of age All Phase 3
I Ida Voss, MD

Semaglutide Treatment for Hyperglycaemia After Renal Transplantation

Background: Post-transplant hyperglycaemia occurs frequently in renal transplant recipients within the first two weeks after transplantation. Standard-of-care is primarily based on insulin treatment with the adherent risk of hypoglycaemia and weight gain. Semaglutide produces an effective lowering of plasma glucose in diabetes patients with chronic kidney disease (CKD) and leads …

18 - 80 years of age All Phase 4
J Jessica Vincent, MD

Semaglutide for Post-Smoking Cessation Weight Management

This trial will examine the effect of semaglutide 2.4mg on changes in body weight, body composition, and peripheral and central mechanisms that control appetite, satiety, and food intake in the context of smoking cessation.

18 - 75 years of age All Phase 2
A Apurva Raje

Feasibility of Semaglutide in Advanced Lung Disease

The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question[s] it aims to answer are: Are patients with advanced lung disease able to tolerate semaglutide therapy? Are we able …

18 - 80 years of age All Phase 1/2
S Sabina Frljak, MD, PhD

Mechanisms of Semaglutide Therapy in Heart Failure Patients

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily used for treatment of type-2 diabetes mellitus. GLP-1 receptors are present on pancreatic islet β-cells, δ-cells and α-cells. Their stimulation increases insulin and somatostatin secretion, and decreases glucagon secretion. In addition, GLP-1 receptor agonists appear to have multiple extrapancreatic actions, which …

20 - 80 years of age All Phase 1/2
S Sarah Byberg

Young Adults With Early-onset Obesity Treated With Semaglutide

Introduction The increasing prevalence of obesity is particularly pronounced among adolescents. Currently available treatment options consist of structured lifestyle interventions. However, 25 % of adolescents do not respond to lifestyle treatment, why new effective treatment strategies are needed. Therefore, the aim of this study is to investigate the effect of …

18 - 28 years of age All Phase 4
B Bri Hihara

Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

This trial plans to learn more about the effects of a medication, semaglutide, on cardiovascular function, kidney function, and insulin sensitivity in adults with type 1 diabetes. This medication has been effective in reducing cardiovascular disease and diabetic kidney disease and improving glucose control and BMI in adults with type …

18 - 49 years of age All Phase 3

Simplify language using AI